Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($1.67), $0.02 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $19.35 million versus the consensus estimate of $8.59 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.